Where does Stoke Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$169.77M-438%	-$6.89M+92.3%	$40.57M+138%	$52.48M+151%	$50.27M+146%
Depreciation and amortization	$1.73M-17.2%	$1.77M-18.7%	$1.89M-16.9%	$1.99M-16.1%	$2.09M-14.1%
Stock-based compensation	$34.24M+18.8%	$32.24M+17.4%	$29.53M+11.9%	$28.98M+13.9%	$28.81M+16.3%
Change in accounts receivable	——	——	——	——	$1.36M—
Change in other assets	——	——	——	——	——
Change in deferred revenue	——	——	-$25.58M-168%	-$24.62M-196%	-$17.54M—
Net cash from operating activities	——	——	——	——	$69.54M+183%
Capital expenditures	$871K+154%	$670K+230%	$480K+23.1%	$451K-32.7%	$343K-76.6%
Net cash from investing activities	-$158.84M-51.8%	-$195.91M-80.9%	-$134.85M-44.2%	-$164.85M-237%	-$104.65M-267%
Proceeds from issuance of common stock	$10.8M+336%	$8.6M+400%	$4.61M+298%	$2.26M+83.5%	$2.48M+429%
Net cash from financing activities	$180.34M+37.9%	$97.39M-25.7%	$5.62M-95.9%	$10.66M-91.8%	$130.75M+1,252%
Net increase (decrease) in cash	-$117.06M-221%	-$44.66M+29.4%	-$66.47M-66.3%	-$91.78M-2,723%	$96.46M+1,097%
Depreciation	$1.73M-17.2%	$1.77M-18.7%	$1.89M-16.9%	$1.99M-16.1%	$2.09M-14.1%
Increase Decrease In Accounts Payable Accrued Liabilities And Opertaing Leases	$829K—	$21.29M—	$14.57M—	——	——
Deferred revenue	——	——	-$25.58M-168%	-$24.62M-196%	-$17.54M—
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Reduction In Carrying Amount Of Operating Lease Right Of Use Assets	$2.42M+4.5%	$2.41M+6.3%	$2.34M+2.9%	$2.36M+4.3%	$2.31M+2.4%
Proceeds From Controlled Equity Offering Sales Agreement Net Of Commissions	——	$87.78M+880%	$68.08M+245%	$48.37M+58.5%	$28.66M-30.6%
Proceeds From Issuance Of Common Stock In Controlled Equity Offering Sales Agreement	——	——	——	——	——
Proceeds from issuance of common stock relating to employee stock plans	——	——	——	——	——
Accrued payables for capital expenditures	$789K+862%	$482K+690%	$142K—	$112K—	$82K—
Free cash flow	——	——	——	——	$69.2M+181%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Stoke Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.